Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG
Primary Purpose
Postoperative Atrial Fibrillation
Status
Unknown status
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Dronedarone
Amiodarone
Colchicine
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria:
The study population will include inpatients of the cardiothoracic department scheduled for CABG surgery, both sex, selected randomly according to American Society of Anesthesiologists(ASA) grade II and III
Exclusion Criteria:
- - Liver dysfunction, pregnancy.
- History of allergic reaction to any drug used in this study.
- Emergency procedure
- Preoperative dialysis
- A.F.
- Patients on antiarrhythmic medications
Sites / Locations
- Faculty Of Medicine, Beni-Suef UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
colchicine
Dronedarone
amiodarone
Arm Description
Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
Outcomes
Primary Outcome Measures
AF
incidence of AF
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03905759
Brief Title
Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG
Official Title
Preoperative Colchicine, Dronedarone Or Amiodarone for Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG; A Comparative Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Unknown status
Study Start Date
April 3, 2019 (Actual)
Primary Completion Date
April 10, 2020 (Anticipated)
Study Completion Date
April 10, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
doaa rashwan
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Atrial fibrillation in the postoperative period of myocardial revascularization surgery (AF-POMR) occurs in 10% to 65% of patients, increasing morbidity and mortality after surgery. is associated with an increase in hospital length of stay, and, thus, in costs,and can cause serious clinical complications, such as hypotension, heart failure, stroke and other thromboembolic disorders.Although not completely understood, the electrophysiological mechanism of AF-POMR is believed to be reentry.
Detailed Description
Aim of the study The aim of this work is to study the effect of preoperative Colchicine, Dronedarone or Amiodarone for prophylaxis against postoperative atrial fibrillation in patients undergoing on-pump CABG.
Patients and Methods
Type and site of the study:
This randomized double blinded clinical study will be carried out at Beni-Suef university hospital, after approval by the department of Anesthesiology, Pain management and Surgical ICU, the local ethics and research committee and other involved departments, faculty of medicine, Beni-Suef University.
Study population:
The study population will include inpatients of the cardiothoracic department scheduled for CABG surgery, both sex, selected randomly according to American Society of Anesthesiologists(ASA) grade II and III, between the ages of 40 -60ears.
Exclusion criteria:.
Liver dysfunction, pregnancy.
History of allergic reaction to any drug used in this study.
Emergency procedure
Preoperative dialysis
A.F.
Patients on antiarrhythmic medications
Sample size estimation:
As considered the primary outcome, sample size calculation was done using the comparison of the rate of occurrence of postoperative AF in cases undergoing on-pump CABG pretreated with colchicine, dronedarone or amiodarone. As previously published 19 , the rate of postoperative AF among amiodarone group was 25%, while in colchicine, it was 7% 20. investigators assumed that dronedarone treatment will differ about 20% from amiodarone and selected the least excepted difference to do the calculation. Therefore, the calculation was done based on comparing 2 proportions from independent samples using Chi test, the α-error level was fixed at 0.05 and the power was set at 80%.
Accordingly, the optimum sample size should be 48 cases in each arm. Sample size calculation was done using PS Power and Sample Size Calculations software, version 3.0.11 for MS Windows (William D. Dupont and Walton D. Vanderbilt, USA).
Sampling Technique:
The patients will be randomly divided into three groups, as follows: Group c: Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge ; Group D: Dronedarone (200 mg twice daily starting from day before operation till 5 days after) ; Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery Randomization assignment of patients to Groups C, D and A will be performed with a list of random numbers generated by a computer program's random function. The allocation into the groups and the preparation of the study drug will be performed by an individual who as unrelated to the study. Personnel, patients, and the individual participating in the data collection and data analysis will be blinded to the treatment assignments.
Anesthesia Management The patients will be evaluated preoperatively 1 day before surgery. Electrocardiogram (ECG), pulse oximetry, cannulation of the invasive arterial pressure (20 gauge) from the left radial artery, and peripheral venous access (18 gauge) from the right arm will be inserted into the patient, who will be taken to the operating room on the day of the surgery. After induction of anesthesia and intubation, an 8F central venous catheter will be inserted from the right internal jugular vein. Midazolam (0.05 mg/kg), propofol (2 mg/kg), fentanyl (5 mcg/kg), and rocuronium (0.6 mg/kg) will be used for the induction of anesthesia. Anesthesia will be maintained with a mixture of 2% sevoflurane, 60% oxygen, and 40% air.
All patients will be ventilated with positive pressure. Ventilation parameters will be set as a tidal volume of 8ml/kg and a respiratory rate of 10-12/min, which will be assessed by arterial blood gases. All patients will receive 500 ml ringer lactat before the induction of anesthesia. Thereafter, IV ringer lactate solution will be infused to keep the central venous pressure (CVP) at 10-12 mmHg.
Cardiopulmonary Bypass Management Before cannulation for CPB, 3 mg/kg of heparin will be administered for all patients. When the activated coagulation time will be > 400/sec, it will be passed to the pump.
Nonpulsatile CPB flow rates of 2-2.4 L/min/m2 will be applied, and the mean arterial pressure (MAP) will be kept at 50-60 mmHg. Hematocrit concentration will be maintained at 25-28%. Moreover, mild hypothermia (28-30°C) will be reached during CPB. Myocardial protection will be achieved with intermittent antegradecardtemperature of 37°C will be achieved after surgery, and the patient will be removed from CPB. Following this, coagulation will be provided with protamine; once hemodynamic stabilization (MAP 70-90 mmHg) will be achieved, patients will be brought to the intensive care unit.
Data Collection Methods:
The following parameters will be evaluated and recorded by senior anesthesiologist unaware of the study protocol:
Demographic data (age, sex, and weight)
Perioperative data (operation time, cross-clamp time, EF ).
Post bypass and post operative AF
Hospital stay and death
Statistical analysis Continuous variables will be summarized as mean ± SD and categorical variables Will be expressed as proportion (%). Univariate analyses will be performed by chi-square, student's t-test, Fisher exact test, Mann Whitney test and One-way ANOVA (will be used for comparison between the three groups). SPSS for Windows (version 17; SPSS Inc., Chicago, IL., USA) will be used for statistical analysis. Results will be considered significant if P values are less than 0.05p
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Atrial Fibrillation
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
colchicine
Arm Type
Active Comparator
Arm Description
Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
Arm Title
Dronedarone
Arm Type
Active Comparator
Arm Description
Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
Arm Title
amiodarone
Arm Type
Active Comparator
Arm Description
amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
Intervention Type
Drug
Intervention Name(s)
Dronedarone
Other Intervention Name(s)
amiodarone,colchicine
Intervention Description
Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
Intervention Type
Drug
Intervention Name(s)
Amiodarone
Other Intervention Name(s)
colchicine ,dronedarone
Intervention Description
Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
Intervention Type
Drug
Intervention Name(s)
Colchicine
Other Intervention Name(s)
amiodarone, dorendarone
Intervention Description
Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
Primary Outcome Measure Information:
Title
AF
Description
incidence of AF
Time Frame
change from baseline rhythm at 6 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The study population will include inpatients of the cardiothoracic department scheduled for CABG surgery, both sex, selected randomly according to American Society of Anesthesiologists(ASA) grade II and III
Exclusion Criteria:
- Liver dysfunction, pregnancy.
History of allergic reaction to any drug used in this study.
Emergency procedure
Preoperative dialysis
A.F.
Patients on antiarrhythmic medications
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Doaa A Rashwan, MD
Phone
00201011270763
Email
doaa_rashwan@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Belal Y Mohammed, Msc
Phone
0020124138153
Email
byahia37@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
belal Y Mohammed, Msc
Organizational Affiliation
Faculty of Medicine Beni-Suef University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Faculty Of Medicine, Beni-Suef University
City
Banī Suwayf
ZIP/Postal Code
11391
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
doaa rashwan, md
Phone
00201011270763
Email
doaa_rashwan@hotmail.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
the protocol
IPD Sharing Time Frame
after registration for ever
IPD Sharing Access Criteria
on the web page
Learn more about this trial
Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG
We'll reach out to this number within 24 hrs